Catalyst Pharmaceuticals Story

Macroaxis does not monitor all media channels or aggregates social signals for Catalyst Pharmaceuticals. But even though we do not provide professional-grade financial sentiment analysis on Catalyst Pharmaceuticals, we do publish noise-free headlines that can be used to derive useful patterns or even a trading strategy for Catalyst Pharmaceuticals. Check also Catalyst Pharmaceuticals Hype Analysis, Catalyst Pharmaceuticals Correlation and Catalyst Pharmaceuticals Performance
Catalyst Pharmaceuticals, Inc. A Detailed Look at its Institutional ...
Catalyst Pharmaceuticals, Inc. reached 201.96 versus a 1year low price of 0.51. The stock was last seen 1.99 higher, reaching at 1.54 on Mar. 17, 2017. Stock Value Analysis Catalyst Pharmaceuticals, Inc. The Oracle Examiner The Catalyst Pharmaceuticals Inc Posts Quarterly Earnings Results ... Petro Global News 24

Read More...   

Story Momentum

This media report from distributed on March 20, 2017 was a factor to the next trading day price appreciation.The overall trading delta against the next closing price was 2.41% . The overall trading delta when the story was published against the current closing price is 0.60% .

Similar stores for Catalyst Pharmaceuticals

a day ago at 
A Look at 2 Trending Stocks Catalyst Pharmaceuticals, Inc. NASDAQCPRX ...
Catalyst Pharmaceuticals, Inc. has a consensus outperform rating from 4 Wall Street analysts, and the number of shares currently sold short amount to at least 3.97 of shares outstanding.
over a week ago at 
Catalyst Pharmaceuticals Inc Raised to Buy at Zacks Investment Research
Catalyst Pharmaceuticals logo Catalyst Pharmaceuticals Inc was upgraded by Zacks Investment Research from a hold rating to a buy rating in a report released on Tuesday. Analysts Offer Predictions for Catalyst Pharmaceuticals Inc Q1 2017 Earnings ... - Sports Perspectives Catalyst Pharmaceuticals Inc Given a 3.00 Price Target by Roth Capital ... - BBNS
over three weeks ago at 
Acquisition by Miller Steve of 30000 shares of Catalyst Pharmaceuticals subject to Rule 16b3
Macroaxis News
Filed transaction by Catalyst Pharmaceuticals officer. Grant, award or other acquisition pursuant to Rule 16b3
over a month ago at 
Financials of Aurinia Pharmaceuticals and Catalyst Pharmaceuticals are Getting ...
After hours trading showed a continued rise in the company stock price. Catalyst Pharmaceuticals is a biopharmaceutical company that is currently focused on the development of innovative treatments dealing with rare neuromuscular and neurological ...

Did you try this?

Run Balance Of Power Now

Balance Of Power

Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Hide  View All  Next  Launch Balance Of Power

Price to Book

Price to Book Comparative Analysis
Catalyst Pharmaceuticals is currently under evaluation in price to book category among related companies. Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is accounting value of assets minus liabilities.